- INmune
Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual
Immuno-Oncology Summit in Boston
- Co-founder
and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03,
which is being developed as part of a combination immunotherapy to
potentially reverse resistance to treatment
- The
annual immuno-oncology summit brings together leaders from across the
immunotherapy industry and provides unique opportunities to connect
scientists with the latest discoveries in the field
An international mix of thought leaders and decision makers
from the international immunotherapy and immuno-oncology community are
gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi
slated to deliver several presentations. A news release outlining Tesi’s agenda
at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology
Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company
focused on developing treatments that harness patients’ innate immune systems
to fight disease (http://ibn.fm/4pBdZ).
“We are committed to helping treatment-resistant patients by
advancing the clinical development of combination therapies and other effective
cancer treatments,” Tesi stated in a news release. “I am delighted to have the
chance to present with some of the most prominent leaders in the
immuno-oncology community.”
A fast-growing cancer patient population that is resistant
to checkpoint inhibitors (“CPI”) was the focus of Tesi’s presentation on
Monday, August 5, under the title ‘Targeting Soluble TNF to Improve Efficacy of
Combination Immunotherapy’. During his presentation, Tesi reported positive
preliminary data from the company’s INB03 Phase I clinical trial in cancer
patients (http://ibn.fm/m1Iy3).
“The goal of the Phase I study is to determine, in order of
priority, the safety of INB03 in cancer patients, the dose of INB03 to take
into the Phase II trials in cancer, and evidence of a biologic effect of
INB03,” continued Tesi, who is also INmune Bio’s chief medical officer. “All of
these goals have been met. Using data from this trial, we have begun planning a
Phase II trial using INB03 as part of combination immunotherapy in patients
with cancer.”
The Phase I trial is an open-label, dose-escalation trial in
patients with advanced solid tumors. Patients received INB03, a novel,
second-generation soluble TNF (tumor necrosis factor) inhibitor that works by
leveraging a dominant-negative technology. Positive preliminary data from the
first two cohorts were released. That data will be followed by a final report
later this year as the company advances the program into a Phase II study.
Tesi is also speaking on ‘Next-Generation Immunotherapies’
and ‘Targeting ‘Protector’ Cells of the Innate Immune System’ during the
summit. The Cambridge Healthcare Institute’s annual immuno-oncology summit
brings together leaders from across the immunotherapy industry and provides a
unique opportunity to network with decision-makers, build lasting
collaborations and gain actionable solutions.
INmune Bio also recently attended the 17th Annual Congress
of International Drug Discovery Science & Technology in Japan, where Tesi
gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer
Treatments’. His presentation centered on monotherapy with checkpoint
inhibitors (“CPI”) as an effective treatment option. The combination of CPI and
other therapies may improve outcomes in patients who are unresponsive to
monotherapy, an article explains (http://ibn.fm/EFAdX).
INmune Bio’s product pipeline targets three segments of
concern: Alzheimer’s disease/dementia, which claims 5.5 million patients in the
U.S.; cancer residual disease, which is expected to generate more than 1.7
million new cases yearly; and resistance to immunotherapy. INmune Bio is
currently working on three product platforms: INKmune and INB03, which modify a
patient’s innate immune response to cancer; and XPro1595, which targets
inflammation linked to Alzheimer’s disease.
For more information, visit the company’s website at www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
